Clinical Research Directory

Inclusion Criteria: 1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria. 2. The expected survival time is more than 3 months. 3. Intracranial metastases ≤10. 4. Adequate organ and bone marrow function. Exclusion Criteria: 1. Patients who have used antiangiogenic drugs within the previous 1 month. 2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer). 3. Small cell lung cancer with hilar invasion or hemoptysis. 4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage. 5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment. 6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications. 7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.